Navigation Links
Hologic Announces First Quarter Fiscal 2008 Operating Results
Date:1/31/2008

Revenues, Adjusted Earnings and Backlog Increase to Record Highs

BEDFORD, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX), a diversified medical technologies company specializing in diagnostics, imaging systems and interventional devices dedicated to serving the healthcare needs of women, today announced its results for the quarter ended December 29, 2007.

Highlights of the quarter include:

-- Record revenues of $371.4 million.

-- Merger with Cytyc Corporation on October 22, 2007 contributes $158

million of revenue (for 10 of 13 weeks).

-- Record 384 Selenia full field digital mammography systems installed and

recognized as revenue.

-- Record backlog of $244.5 million for historical businesses

(mammography/breast care/skeletal health).

-- Issued $1.725 billion of convertible senior notes (at 2% interest).

-- Term loan balance reduced to $295 million at December 29, 2007.

-- Reported net loss of $358.6 million due primarily to non-cash charges

related to the Cytyc merger.

-- Hologic was added to the Nasdaq-100 index(R) on December 24, 2007.

First quarter fiscal 2008 revenues totaled $371.4 million, a 128% increase when compared to revenues of $163.2 million in the first quarter of fiscal 2007. The increase was primarily attributable to the inclusion of Cytyc revenues for the period from October 22, 2007 (the merger date) to December 29, 2007, which approximated $158 million. For the first quarter of fiscal 2008, Hologic reported a net loss of $358.6 million, or $3.31 per diluted share, compared with net income of $16.1 million, or $0.30 per diluted share, in the first quarter of fiscal 2007. Included in t
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens
2. Hologic to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...T.LOUIS,Nov.24/PRNewswire-FirstCall/--Sigma-Aldric...SDAQOMXconferenceonTuesday,December1stat1:45PMGMTi...liveaudiobroadcastovertheInternetavailableat http...anclickthe"Webcast"icontoaccessthisfile. ,, A...enceandHighTechnologycompany.Itschemicalandbiochem...
(Date:11/24/2009)...EYKJAVIK,Iceland,November24/PRNewswire-FirstCall/-...theapprovalofallofits,"firstday"motionsbytheU.S.Ba...tcyCourt").deCODElastweekfiledavoluntarypetitionfo...odewiththe,BankruptcyCourt. , Theordersissued...erateitsbusinessduringtheChapter11proceedings.Inpa...
(Date:11/24/2009)...ANMATEO,Calif.,Nov.24/PRNewswire-FirstCall/--Neuro...focusedondevelopingandcommercializingnovelpainmana...residentandChiefExecutiveOfficer,isscheduledtopres...,tobeheldDecember1-2,2009atTheNewYorkPalaceHotelin...ri,ChiefFinancialOfficer,willbeavailabletorespondt...
(Date:11/24/2009)...EATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCorp.an...pmentAuthority(OPDA)wererecentlyawarded$2millionby...ard(CERB)inaprivate/publicpartnershiptoconstructth...olnCounty,WA. ,, "Thisinvestmentwillsignificant...0greenjobstoLincolnCounty,"saidBlueMarbleEnergyCEO...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...rom group funded by US De...ace, the world,s leading,online community and care...d today the incorporation of useful career resourc...Work Portal, a national Web site created,by the Sa...intended to aid,and assist biotechnology employers...
...ciences, Inc. (Nasdaq: PBIO ) ("PBI" or "the Comp...ooperative Research and Development Agreement,(CRA...nstitute of,Infectious Diseases (USAMRIID). Resear... of the Company,s patented pressure cycling techno... ("ProteoSolve-SB") has resulted in,the simultaneo...
...st in therapeutic efficiency, quality and safety o...t environmental contamination, drive the biotechno...ience spiraling growth given the recent success of...products presently in the pipeline. , ...r 11, 2008 -- Biotechnology industry is regarded a...
Other Biology Technology:BioSpace Launches Life Science Career Content and Resources from the Biotech Work Portal 2BioSpace Launches Life Science Career Content and Resources from the Biotech Work Portal 3Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 2Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 3Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 4Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 5Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 2Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 3Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 4
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wildlife Con...evealing that the last remaining population of Sib... to the rising tide of poaching and habitat loss. ...rm Russian officials of what needs to be done to p...t cat. , The report was released by...
(Date:11/24/2009)...tes fish food is a matter of debate. A high-profil...most 50 percent of their carbon from trees and lea...rrestrial and aquatic ecosystems. , But new rese...is not likely to be true. Algae provide a much ric...g to research published this week in the Proceedi...
(Date:11/24/2009)...is available in Spanish . , The presence of...f inflammatory substances in the blood, hinders th... a research project of the University of Navarra c...at the School of Pharmacy. , The project, entitl...ion to the control of body weight and inflammation...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3It can be predicted the reaction obese patients will have to a diet 2Growth in the Parkinsons Disease Drug Market Fueled by the Launch of Several New Therapies Will be Offset by Generic Erosion of Key Agents 48287 1Growth in the Parkinsons Disease Drug Market Fueled by the Launch of Several New Therapies Will be Offset by Generic Erosion of Key Agents 48287 2Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 48285 1Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 48285 2Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 48285 3Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 48285 4Nektar Therapeutics Promotes Lorianne Masuoka M D to Chief Medical Officer 12543 1Nektar Therapeutics Promotes Lorianne Masuoka M D to Chief Medical Officer 12543 2Nektar Therapeutics Promotes Lorianne Masuoka M D to Chief Medical Officer 12543 3
..., Sick people often lose their sense of smell and...hey would not be able to feed on humans and spread...oking for an insect disease that will infect mosqu... by a recent $100,000 grant from the Bill and Meli...ns Initiative, the researchers were among 81 proje...
..., Australian rabbits have had everything but the ...tosis knocked them about but they bounced back. Th...he calicivirus., Now Dr Tanja Strive from CSIRO E...earch Centre has found that some rabbits in cool, ...s them immunity to RHD., "We knew that RHD was no...
..., Scientists at the University of Liverpool have ...chnology could be used to improve the effectivenes...ves the manipulation of matter at sizes close to m... clusters of molecules. The collaborative project ...ogy will apply nanotechnology techniques to develo...
Other Biology News:Penn State entomologists seek fungus to blunt mosquitoes' sense of smell 2Rabbits on the back foot -- but naturally they're fighting back 2University awarded £1.7M to develop nanotechnology for use in health care 2
ReBlot™ Western Blot Recycling Kit from Upstate
EGTA, Molecular Biology Grade from Research Organics, Inc.
EGTA from Research Organics, Inc.
PARP Cleavage Immunoblotting Assay Kit from Upstate
Biology Products: